Table 3.
Overview of studies including immunologic markers as predictive biomarkers for chemotherapy response in pancreatic cancer patients.
| Author | Year of Publication | Number of Patients | Stage of Disease | Treatment | Biomarker |
|---|---|---|---|---|---|
| Palagani [84] | 2012 | 4 | Metastatic | 5-FU + oxaliplatin + irinotecan and/or avastin | CD44+ cells |
| Vizio [78] | 2012 | 58 | LAPC + metastatic | Gemcitabine (n = 28) Gemcitabine + oxaliplatin (n = 23) Bevacizumab + capecitabine + radiation (n = 6) 5-FU + levofolinate calcium (n = 1) |
IL-23 IL-17a TGF-β1 |
| Wittwer [89] | 2013 | 68 | LAPC + metastatic + recurrence | Gemcitabine Gemcitabine + erlotinib Gemcitabine + everolimus Gemcitabine + axitinib Capecitabine Capecitabine + erlotinib Nab-paclitaxel |
sRAGE |
| Wittwer [88] | 2013 | 68 | LAPC (n = 9) + metastatic (n = 42) + recurrence (n = 17) | Gemcitabine Capecitabine |
sRAGE |
| Azzariti [47] | 2016 | 27 | Metastatic | FOLFIRINOX (21) Gemcitabine + nab-paclitaxel (6) |
sCD40L |
| Gao [75] | 2017 | 122 | LAPC + metastatic | Gemcitabine (n = 119) Fluorouracil (n = 1) Capecitabine (n = 1) S1 (n = 1) |
NLR |
| Usul Afsar [79] | 2017 | 20 | Metastatic | Gemcitabine (n = 11) Gemcitabine + platinum (n = 6) Gemcitabine + capecitabine (n = 3) |
IL-18 |
5-FU = fluorouracil, LAPC = locally advanced pancreatic cancer, IL = interleukin, sRAGE = soluble receptor for advanced glycation end products, NLR = neutrophil-to-lymphocyte ratio, IL = interleukin, S1 = tegafur, gimeracil and oteracil potassium.